Claims
- 1. An isolated nucleic acid encoding a B7-2 fusion protein comprising a nucleotide sequence encoding a first peptide having a B7-2 activity and a nucleotide sequence encoding a second peptide corresponding to a moiety that alters the solubility, binding affinity or valency of the first peptide.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT/US94/08423 |
Jul 1994 |
WO |
|
RELATED APPLICATIONS
[0001] This application is a continution-in-part of U.S. Ser. No. 08/280,757, entitled “Novel CTLA4/CD28 Ligands and Uses Therefor” filed Jul. 26, 1994, which is a continuation-in-part of U.S. Ser. No. 08/109,393, entitled “Novel CTLA4/CD28 Ligands and Uses Therefor” filed Aug. 19, 1993, which is a continuation-in-part of U.S. Ser. No. 08/101,624, also entitled “Novel CTLA4/CD28 Ligands and Uses Therefor”, filed Jul. 26, 1993. This application is also a continution-in-part of U.S. Ser. No. 08/147,773, entitled “Tumor Cells Modified To Express B7-2 And B7-3 With Increased Immunogenicity And Uses Therefor” filed Nov. 3, 1993. The contents of each of these applications is incorporated herein by reference.
GOVERNMENT FUNDING
[0002] Work described herein was supported under CA-40216-08 awarded by the National Institutes of Health. The U.S. government therefore may have certain rights in this invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08479744 |
Jun 1995 |
US |
Child |
09425762 |
Oct 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09425762 |
Oct 1999 |
US |
Child |
10429079 |
May 2003 |
US |
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
08280757 |
Jul 1994 |
US |
Child |
08479744 |
Jun 1995 |
US |
Parent |
08109393 |
Aug 1993 |
US |
Child |
08280757 |
Jul 1994 |
US |
Parent |
08101624 |
Jul 1993 |
US |
Child |
08109393 |
Aug 1993 |
US |
Parent |
08147773 |
Nov 1993 |
US |
Child |
08479744 |
|
US |
Parent |
08109393 |
Aug 1993 |
US |
Child |
08147773 |
Nov 1993 |
US |